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Trial and Error
How to Avoid Commonly Encountered
Limitations of Published Clinical Trials
Sanjay Kaul, MD, George A. Diamond, MD
Los Angeles, California
The randomized controlled clinical trial is the gold standard scientific method for the evaluation of diagnostic
and treatment interventions. Such trials are cited frequently as the authoritative foundation for evidence-based
management policies. Nevertheless, they have a number of limitations that challenge the interpretation of the
results. The strength of evidence is often judged by conventional tests that rely heavily on statistical significance.
Less attention has been paid to the clinical significance or the practical importance of the treatment effects.
One should be cautious that extremely large studies might be more likely to find a formally statistically significant
difference for a trivial effect that is not really meaningfully different from the null. Trials often employ composite
end points that, although they enable assessment of nonfatal events and improve trial efficiency and statistical
precision, entail a number of shortcomings that can potentially undermine the scientific validity of the conclu-
sions drawn from these trials. Finally, clinical trials often employ extensive subgroup analysis. However, lack of
attention to proper methods can lead to chance findings that might misinform research and result in suboptimal
practice. Accordingly, this review highlights these limitations using numerous examples of published clinical tri-
als and describes ways to overcome these limitations, thereby improving the interpretability of research
findings. (J Am Coll Cardiol 2010;55:415–27) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.065c
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hhe randomized controlled trial (RCT) is the apotheosis of
cientific progress in clinical medicine. Such trials are key
rivers of modern cardiovascular practice, since they are
ited frequently as the authoritative foundation for
vidence-based management policies. Although the ran-
omization process minimizes the imbalance in measured
nd unmeasured confounding variables, thereby allowing
ne to infer causation, not just association, a number of
imitations nevertheless serve to challenge the interpretation
f the results. Three particular technical limitations are the
ubject of this review. First, strength of evidence is often
udged by conventional tests that rely heavily on statistical
ignificance and estimation of confidence intervals (CIs).
ess attention has been paid to the clinical significance or
he practical importance of the treatment effects. Second,
omposite end points are often used to increase the propor-
ion of outcome events and thereby reduce requisite sample
ize. Although this practice improves trial efficiency and
tatistical precision, it entails a number of shortcomings that
an undermine the scientific validity of the conclusions
rawn from these trials. Finally, additional exploratory
ubgroup analyses are frequently performed without suffi-
rom the Division of Cardiology, Cedars-Sinai Medical Center, and the David
effen School of Medicine, University of California, Los Angeles, California. Dr.
iamond has served on the Speaker’s Panel for Merck and Schering-Plough.s
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ccepted June 1, 2009.ient attention to the reliability of these subordinate analy-
es. This leads to the reporting of chance findings that
ncourage suboptimal patterns of practice. In this review, we
ighlight each of these limitations using numerous examples
f published clinical trials and propose practical ways to
void them and help improve the interpretation of the
ublished findings.
mphasize Clinical Importance
ver Statistical Significance
he conventional approach to assessing the strength of the
ssociation between an intervention and outcome (the
vidence) focuses on p values and CI (1–4). A p value or
bserved significance level provides a measure of the incon-
istency of the data with respect to a specific hypothesis. In
linical trials, investigators pre-specify a significance level
most commonly 0.05) that represents the maximum prob-
bility they will tolerate of rejecting a hypothesis when it is
n fact true. Some have suggested that p values provide a
easure of the strength of the evidence against the null
ypothesis; the smaller the p value, the stronger the evi-
ence against the null hypothesis. For example, Sterne and
mith (3) suggest that a p value of 0.05 need not provide
trong evidence against the null hypothesis, but it is reason-
ble to say that a p value 0.001 does. In contrast, others
ave cautioned that because p values are dependent on
ample size, a p value of 0.001 should not be interpreted as
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jecting the null hypothesis than
one of 0.05 (4).
In contrast to the well-established
standards for decisions regarding
statistical significance, no particu-
lar guidelines exist for deciding
what magnitude of difference is
“clinically significant” or “practi-
cally important” (1–6). The latter
decision depends upon the quan-
titative magnitude of the treat-
ment effect and the associated
context—the seriousness and the
frequency of the outcome of inter-
est and the benefit-risk-cost pro-
file. Because of the inherently sub-
jective and context-specific nature
of these judgments, investigators
have understandably been reluc-
tant to establish fixed boundaries
for what constitutes a clinically
significant difference.
An unintended consequence of this lack of an established
tandard has been an erroneous tendency to equate statisti-
al significance with clinical significance. In some instances,
tatistically significant results may not be clinically impor-
ant (e.g., small differences in studies with large sample
ize), and conversely, statistically insignificant results do not
ompletely rule out the possibility of clinically important
ffects (e.g., large differences in studies with small sample
ize) (6). Ideally, assessment of both statistical and clinical
ignificance should be used to appraise the strength of the
vidence and to aid in optimal utilization of therapeutic
nterventions in clinical practice.
Consider the TACTICS–TIMI 18 (Treat Angina With
ggrastat and Determine Cost of TherapyWith an Invasive
r Conservative Therapy–Thrombolysis In Myocardial In-
arction 18) trial, a randomized trial of early invasive versus
arly conservative management of patients with acute cor-
nary syndromes (ACS) (7). In designing the trial, the
nvestigators powered the study to detect a 25% relative risk
eduction, presumably representing their estimate of a
inimum clinically important difference (MCID) in out-
ome. Upon conducting this trial, a total of 177 events
15.9%) were observed among 1,114 patients assigned to
arly invasive management versus 215 events (19.4%)
mong 1,106 patients assigned to early conservative man-
gement (7). The relative risk reduction for this 3.5%
bsolute difference was 18% (95% CI: 2% to 32%), and this
as determined to be statistically significant (p  0.028).
he investigators thereby concluded that early invasive
anagement is superior to early conservative management.
owever, the key question that the thoughtful clinician is
nterested in is, “What is the probability that early invasive
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass graft surgery
CI  confidence interval
LMCA  left main coronary
artery
MACE  major adverse
cardiac event
MCID  minimum clinically
important difference
MI  myocardial infarction
NNT  number needed to
treat
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trial
TVR  target vessel
revascularizationanagement is associated with a ‘clinically-important’ ben-fit over early conservative management?” Simply stated, is
he 18% risk reduction observed in this study “clinically
mportant?”
Sackett (6) has proposed the use of CIs to answer this
uestion. According to this approach, if the summary
reatment effect is large enough to exclude values smaller
han the MCID, and not just the null value of zero, then the
reatment provides both a statistically and clinically signif-
cant benefit. Using this approach, Figure 1A classifies
reatment effects into the following categories: “statistically
ot significant and clinically not important” (example A,
here the entire CI lies to the right of the MCID and
rosses the null line, thus ruling out any important benefit),
Figure 1
Statistically Significant and Clinically Important
Treatment Benefits, and Bayesian Analysis of
Clinical Importance in the TACTICS–TIMI 18 Trial
(A) Graphic demonstration of statistically significant and clinically important
treatment benefits. Five trial results (A to E) and their interpretation with refer-
ence to zero effect (a risk ratio of 1.0) and a minimal clinically important differ-
ence (MCID) of 15% relative risk reduction (corresponding to a risk ratio of
0.85) are shown. Treatment effects (double arrows) are expressed as 95%
confidence intervals. (B) Bayesian analysis of clinical importance in TACTICS–
TIMI 18: Probability density plot for the difference in outcomes between the 2
management strategies is shown using the Bayesian approach (a noninforma-
tive Gaussian prior probability distribution with mean  0 and SD  10). The
probability for any given threshold (d) can be computed in terms of the area
under the probability density curve. The light shaded area to the left of log
odds ratio 0 (equivalent to odds ratio of 1) indicates a 98.6% probability of d
0% benefit and the dark shaded area to the left of log odds ratio 0.35
(equivalent to odds ratio of 0.71 or relative risk of 0.75) indicates a 17% prob-
ability of d 25% benefit. (C) Posterior probabilities for a range of threshold of
benefit are graphically represented. The probability of d 25% risk reduction is
shown as an open circle (17%).
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February 2, 2010:415–27 Limitations of Megatrialsstatistically not significant but may be clinically important”
example B, where the CI crosses the MCID as well as the
ull lines consistent with an indeterminate effect), “statisti-
ally significant but not clinically important” (example C,
here the entire CI lies to the right of the MCID but does
ot cross the null line), “statistically significant and may be
linically important,” (example D, where the CI is centered
o the left of the MCID and does not cross the null), and
statistically significant and clinically important” (example
, where the entire CI lies to the left of the MCID). Most
linical trials are only large enough to generate C- or D-type
esults, and E-type results are only achieved in meta-
nalyses of several RCTs (6). According to this schema, the
reatment benefit observed with early invasive versus early
onservative management in the TACTICS–TIMI 18
tudy is statistically significant and may be clinically impor-
ant because the 95% CI contains the MCID of 25% relative
isk reduction (example D), but is not assured, because all
alues less than the MCID are not excluded with sufficient
onfidence.
Another index, the number needed to treat (NNT) or the
umber needed to harm, has also been used to assess clinical
mportance (8). These indexes and their 95% CIs are
alculated as the inverse of the absolute risk differences. The
ros and cons of such indexes have been reviewed previously
8). In general, treatment interventions are deemed to be
linically important when the number needed to harm is
NNT or when the NNT is 50. However, these
udgments are context-specific (with respect to disease and
utcome severity) and are influenced by the benefit-risk-cost
rofile of intervention and the duration of follow-up.
Alternatively, we have advocated the use of Bayesian
nalysis to estimate probabilities for a range of clinically-
mportant treatment effects (1). Briefly, such inferences are
redicated on Bayes’ theorem, which postulates that the
osterior probability of any given hypothesis is directly
elated to its prior probability based on previous knowledge
nd the empirical evidence generated from within the study.
sing a noninformative prior, indicating that all treatment
ffects are equally likely—an essentially flat distribution—
ermits the posterior to be determined entirely by the study
ata, as in the classical frequentist analysis. Unlike the
requentist approach, however, the Bayesian approach al-
ows one to specify the probability for any given threshold of
linical importance (1,5,9). Although CI is often interpreted
n this manner (as in Sackett’s approach [6]), the correct
nterpretation of a 95% CI from a frequentist perspective is
hat 95% of all CI limits derived from an unlimited number
f repeated experiments would contain the true parameter.
t does not actually ascribe any probability to the value of the
arameter itself (5).
As illustrated in Figure 1B, Bayesian analysis computes
he probability for any given threshold in terms of the area
nder the probability density curve (1,5,9), and can display
his probability graphically across a range of such thresholds
s shown in Figure 1C. The results indicate a 98.6% chance shat the risk reduction is0 (1 minus the 1-sided p value of
.028/2)—but only a 17% chance it is 25% (the MCID
hreshold). Moreover, the posterior probability for benefit
alls as the threshold for benefit increases (85% chance of
10%, 67% chance of15%, and 40% chance of20% risk
eduction). Thus, although a conventional frequentist anal-
sis shows that early invasive management is associated with
statistically significant reduction in outcome, Bayesian
nalysis helps clarify whether the benefit is clinically impor-
ant. Given these posterior probabilities and the important
ide effects of cost and bleeding, some clinicians might opt
ot to use an invasive strategy, despite its statistically
ignificant benefit. In contrast, if invasive management
ere inexpensive and safe, clinicians might still decide to
se it, even though there is a 95% chance that it pro-
ides an important magnitude of benefit. Thus, Bayesian
nalysis provides a straightforward, patient-, physician-, and
ontext-specific statement of clinical importance and com-
lements the frequentist analysis in improving the interpre-
ation of the data and informing clinical decision making
1,5,9).
Table 1 compares the statistical significance and clinical
mportance of treatment interventions for ACS based on the
esults of RCTs and meta-analyses (10–14). A relative
eduction of 15% in recurrent adverse events was consid-
red clinically important (15). Statistically significant differ-
nces were observed for 3 of 5 interventions—aspirin being
he only treatment intervention providing both statistically-
ignificant and clinically-important benefits. Two examples
ighlight a disconnect between statistical significance and
linical importance. Whereas treatment with unfractionated
eparin was not statistically significant despite a large risk
eduction (owing to relatively small sample size) (11), the
robability of 15% risk reduction was 87%, consistent
ith example B in Figure 1A (statistically not significant but
ay be clinically important). In contrast, although treat-
ent with platelet glycoprotein IIb/IIIa inhibitor was sta-
istically significant despite a modest risk reduction (due to
arge sample size) (13), the probability of 15% risk
eduction was only 4%, consistent with example C in Figure
A (statistically significant but not clinically important).
In summary, while statistical significance tells us whether
difference is likely to be real, it does not place that reality
nto a meaningful clinical context by telling us whether the
ifference is small or large, trivial or important. A formal
valuation of clinical importance (using frequentist CIs, the
NT and the number needed to harm indexes, or Bayesian
robabilities), given the overall risk-benefit-cost profile of
ach therapeutic intervention, should be included in the
nalysis, interpretation, and presentation of the results of
linical trials. To this end, we suggest that explicit standards
f evidence be developed that encourage not only robust
rial design and statistical methodology but also emphasize
he explicit assessment of clinical importance relative to
ome pre-defined MCID threshold.
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Limitations of Megatrials February 2, 2010:415–27Toward this end, it might seem convenient to define this
hreshold as the minimum detectable difference employed in
he design of the trial. Unfortunately, however, the mini-
um detectable difference is often selected by trialists on
urely pragmatic grounds such as financial constraints,
estrictions in available candidates, and limitations in
ollow-up duration—allowing the design of a trial with
rugal sample size requirements—and does not necessarily
eflect the MCID from the perspective of the practitioner or
he patient. The optimal thresholds of clinical importance
ight well vary from disease to disease, treatment to
reatment, outcome to outcome, physician to physician, and
atient to patient. Thus, lower thresholds of importance
ight attach to the reduction in mortality or serious
rreversible morbid events such as Q-wave myocardial in-
arction (MI) or stroke versus higher thresholds for reduc-
ion in reversible and less serious morbid events such as
ecurrent hospitalization, asymptomatic periprocedural tro-
onin elevation, or refractory ischemia. Ideally, assessment
f both statistical significance and clinical importance
hould aid in optimal utilization of therapeutic interventions
n clinical practice.
mploy Appropriate Composite End Points
omposite end points are measurable events that lie on a
athophysiologic spectrum and allow for parsimonious
ummarization of treatment effects; in other words, they can
ensibly be added together as being aspects of the same
nderlying biologic process to quantify the overall treatment
ffect. Composite end points are frequently used in clinical
rials (16–22), with 1 recent survey reporting that 37% of
he 1,231 trials published over 7 years used composite
utcomes (21). Such use reduces the sample size and cost
equirements of clinical trials and is thereby thought to
mprove trial efficiency and help facilitate the formal evalu-
tion and ultimate availability of effective new treatments.
The typical cardiovascular trial combines “hard” but
tatistical Versus Clinical SignificanceTable 1 Statistical Versus Clinical Significance
Intervention
Control
(%)
Rx
(%)
Summary Risk Rati
(95% CI)
1. ASA vs. placebo (n  2,856) (10,11) 12.8 5.5 0.43 (0.33–0.56)
2. ASA  UFH vs. ASA (n  1,353) (11) 10.4 7.9 0.67 (0.44–1.02)
3. ASA  UFH  clopidogrel vs.
ASA  UFH (n  12,562) (12)
11.4 9.3 0.82 (0.74–0.92)
4. ASA  UFH  GPI vs. ASA  UFH
(n  27,051) (13)
11.8 10.5 0.91 (0.86–0.99)
5. ASA  clopidogrel  UFH vs.
ASA  clopidogrel  enoxaparin
(n  10,027) (14)
14.5 14.0 0.96 (0.86–1.06)
ummary risk ratios are derived from random-effects meta-analysis except for #3 and #5, which ar
ayesian analysis, and interpretation of confidence intervals (CIs) is based on schema described
ASA aspirin; GPI glycoprotein IIb/IIIa inhibitor; MCIDminimum clinically important differen
eparin.nfrequent end points such as death, Q-wave MI, disabling itroke, and emergency coronary artery bypass graft surgery
CABG) with “soft” but more frequent end points such as
eintervention, periprocedural MI (e.g., biomarker eleva-
ion), recurrent angina, and rehospitalization. Because of
heir greater frequency, these less important disparate out-
omes often drive the effect of therapy on the composite. A
ystematic review of 114 cardiovascular trials that used
omposite end points reported a moderate to large gradient
n the hierarchy of clinical importance of component events
n nearly 40% of the trials (19). Of the 27 trials that reported
statistically significant difference in the composite out-
omes, only 7 were driven by hard outcomes.
Major adverse cardiac events (MACE) are arguably the
ost commonly used composite end point in cardiovascular
esearch (22). There is no consensus definition of MACE,
et its use has become virtually pervasive in cardiovascular
esearch in the last 2 decades. At the broadest level,
efinitions of MACE in use today include end points that
eflect both the safety (death, MI, stroke) and effectiveness
target vessel revascularization [TVR], restenosis, recurrent
schemia, rehospitalization) of various treatment ap-
roaches. Three recent literature reviews revealed that
lthough death and MI were included in most definitions of
ACE (19,21,22), inclusion of the remaining components
as highly variable, thereby contributing to significant
eterogeneity across trials. Even the definition of MI was
ot consistent. Very few trials use the more reliable Q-wave
riterion versus the less reliable non–Q-wave and/or cardiac
iomarker criterion to define MI (22). Such use opens
nvestigators and sponsors to the charge of “gaming” their
rials by inflating the number of (arguably unimportant)
utcome events, thereby increasing statistical power (22).
ecause varying definitions of composites such as MACE
ead to substantially different conclusions, some have called
or a reappraisal of their use (22).
The construction of the composite end point is generally
ased on the premise that each component end point is
Value
NNT
(95% CI)
Pr
(d >MCID)
Interpretation of
Confidence Intervals
0.01 14 (11–19) 100% Statistically significant and clinically
important (E)
0.06 44 (–18) 87% Statistically not significant but may be
clinically important (B)
0.01 54 (35–120) 76% Statistically significant and may be
clinically important (D)
0.012 73 (48–157) 4% Statistically significant but not
clinically important (C)
0.43 184 (–52) 1% Statistically not significant and
clinically not important (A)
on the CURE trial and the SYNERGY trial, respectively. Posterior probabilities (Pr) are derived from
e 1A.
5% relative risk difference; NNT number needed to treat; Rx treatment; UFH unfractionatedo
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February 2, 2010:415–27 Limitations of Megatrialsriteria need to be fulfilled (18–21): 1) each component
hould be of comparable clinical importance; 2) each com-
onent should occur with similar frequency; and 3) each
omponent should be similarly sensitive to treatment inter-
ention. All 3 criteria are seldom fulfilled.
Figure 2 illustrates the interpretation of composite out-
omes in 3 typical cardiovascular trials. The Stent PAMI
Stent–Primary Angioplasty for Myocardial Infarction) trial
as designed to assess whether primary stenting was supe-
ior to primary balloon angioplasty in patients with acute
T-segment elevation MI (23). The combined primary end
oint of death, reinfarction, disabling stroke, or ischemia-
riven TVR at 1 year occurred in fewer patients in the stent
roup than in the angioplasty group (12.6% vs. 20.1%, p 
.005) (23). Examination of the data in Figure 2A reveals
hat the treatment differences were primarily attributable to
ifferences in TVR (p 0.0005), the most prevalent but the
east important component, with little or no impact on
einfarction (p  0.7) or stroke (p  0.83) and death being
ffected negatively (p 0.07). A formal assessment revealed
eterogeneity of treatment effect across components of the
omposite end point (p  0.002). Thus, there was a large
radient in clinical importance, prevalence, and treatment
ffect across individual components. This trial highlights
hy combining end points with varying pathophysiology
uch as TVR (restenosis) and mortality (restenosis rarely
eads to death) may not be advisable.
In contrast, no large gradient in clinical importance or
reatment effect across components of the triple composite
nd point of cardiovascular death, nonfatal MI, or stroke
as observed in the HOPE (Heart Outcomes Prevention
valuation) trial that compared ramipril versus placebo for
,297 patients at high risk of cardiac events (24) (Fig. 2B),
hereby supporting the credibility and validity of the com-
osite end point.
These caveats become even more challenging in instances
here efficacy end points are combined with safety end
oints to assess “net clinical benefit.” In such cases, the focus
n net clinical benefit has the potential of masking an
ncrease in harmful effect, particularly when the offsetting end
oints do not have a similar clinical impact. One such example
s shown in Figure 2C. In the TRITON–TIMI 38 (Trial to
ssess Improvement in Therapeutic Outcomes by Optimizing
latelet Inhibition With Prasugrel–Thrombolysis In Myocar-
ial Infarction 38) trial, 13,608 patients with ACS were
andomly assigned to prasugrel, a new thienopyridine, or to
lopidogrel (25). The benefit of prasugrel in the TRITON–
IMI 38 trial was driven by nonfatal MI—nearly one-half
f which were periprocedural biomarker elevations of ques-
ionable clinical relevance—with little or no impact on
ll-cause death or nonfatal stroke; however, non-CABG
hrombolysis In Myocardial Infarction (TIMI) major
leeding—arguably more serious than the biomarker
levations—was significantly increased. A more complete
ccounting of bleeding by including TIMI minor and
inimal bleeding in the composite end point would likely save an important influence on the analysis of net clinical
enefit (25,26).
The unconventional use of a composite efficacy and safety
utcome poses even greater challenges in the assessment of
oninferiority. Typically, the noninferiority claim is con-
ned to efficacy alone. Although combining efficacy and
afety into 1 composite outcome inflates the event rate and
hereby enhances trial feasibility, it can often be misleading
ecause drugs that are relatively ineffective but safer can be
ade to appear as good as or even better than effective drugs
27). This is illustrated in the REPLACE-2 (Randomized
valuation in Percutaneous Coronary Intervention Linking
ngiomax to Reduced Clinical Events) and the ACUITY
Acute Catheterization and Urgent Intervention Triage
trategy) trials, in which the difference in major bleeding
vents (statistically significant 43% and 47% relative reduc-
ions, respectively, in favor of bivalirudin) exceeded the
ifference in MI (statistically nonsignificant 13% and 9%
elative increase, respectively), thereby biasing the assess-
ent of noninferiority in favor of bivalirudin compared with
ts active comparator (27).
Table 2 summarizes the results of 6 RCTs in which the
rimary outcome of interest was a composite end point. In
trials, there was no significant heterogeneity in treatment
ffect across the components (7,28). In contrast, there was
ignificant heterogeneity in 4 trials (25,29–31), with the
eduction in the composite end point being typically driven
y the most prevalent and arguably the least important
omponent (29–31). In 2 trials, death, the most important
nd point, was affected adversely (30,31).
Heterogeneity in treatment effects across the component
vents has important regulatory implications. For example,
he composite end point in the evaluation of losartan in the
IFE (Losartan Intervention for End Point Reduction in
ypertension) study was driven by the impact on nonfatal
troke only. Thus, the subsequent regulatory labeling of
osartan was restricted to prevention of nonfatal stroke and
ot the original claim for the triple end point.
Inappropriate use of composite end points sometimes
eads to an unfounded illusion of benefit. The use of the
ACE composite end point in the bare-metal stent versus
irolimus-eluting stent trial SIRIUS (Sirolimus-Eluting
alloon Expandable Stent in the Treatment of Patients
ith De Novo Native Coronary Artery Lesions) (31)
Table 2) could erroneously lead one to conclude that the
irolimus-eluting stent is significantly better at reducing
eath, MI, stent thrombosis, and target lesion revascular-
zation in totality, even though the statistically significant
ffect on MACE is driven primarily by a reduction in target
esion revascularization alone. The potential for misleading
onclusions depending on the study-specific definition of
ACE is not trivial (22).
The common statistical approach of using equal weights
o combine disparate constituent components of a compos-
te end point is decidedly counterintuitive. A potential
olution to this problem is to assign meaningful weights to
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Limitations of Megatrials February 2, 2010:415–27he components. Such approaches, however, can be highly
ubjective, thereby lending themselves to intellectual gerry-
Figure 2 Composite End Point Analysis for 3 Trials: Stent PAM
Data for the composite end point and the individual component end points are sho
derived from Cochran’s Q chi-square test and is implied at p  0.10; I2 quantifies
fidence interval; MI  myocardial infarction; TVR  target vessel revascularizationandering (19,27,32,33). Thus, these weights need to be crospectively agreed upon based on clinical and statistical
onsiderations that impact the power of the test and
PE, and TRITON–TIMI 38
r 3 trials: (A) Stent PAMI, (B) HOPE, and (C) TRITON–TIMI 38. Heterogeneity is
pact of heterogeneity. Data for stent PAMI at 1 year of follow-up (23). CI  con-I, HO
wn fo
the im
.onsequently the size of the trial.
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February 2, 2010:415–27 Limitations of MegatrialsSuch an approach is illustrated in Figure 3 for the primary
fficacy end point in the TRITON–TIMI 38 trial. Here,
eath was given the highest weight of 1.0, followed by an
ntermediate weight for stroke (0.5). Myocardial infarction
as given a weight of 0.06 on the basis of the case fatality
ate for MI (74 of a total of 1,609 MIs were fatal) (25). The
ata show no statistically significant difference between the
groups with respect to this weighting. Varying the weight
f stroke from 0.1 to 1.0 had no material impact on the
esults. A sensitivity analysis demonstrates a statistically
ignificant difference in favor of prasugrel only at an MI
eight of 0.4 or more—in other words, only when MI is
onsidered nearly one-half as important as death, which is
ighly unlikely given the case fatality rate of only 6%. Using
similar weighting scheme, we previously demonstrated
hat a statistically significant difference in favor of drug-
luting stents over bare-metal stents in the SIRIUS trial was
bserved only at a revascularization weight of 0.5 or more
omposite End Point AnalysisTable 2 Composite End Point Analysis
Treatment
TACTICS–TIMI 18 (early invasive vs. conservative
management in ACS) (7)
Composite 177/1,114 (15.9%)
Death 37/1,114 (3.3%)
MI 44/1,114 (3.9%)
RI 96/1,114 (8.6%)
PRISM-PLUS (tirofiban vs. placebo in ACS) (28)
Composite 100/773 (12.9%)
Death 15/773 (1.9%)
MI 23/773 (3.0%)
RI 62/773 (8.0%)
LIFE (losartan vs. atenolol) (29)
Composite 508/4,605 (11.0%)
CV death 204/4,605 (4.4%)
Stroke 232/4,605 (5.1%)
MI 198/4,605 (4.3%)
TIME (invasive versus medical therapy for elderly patients
with chronic symptomatic CAD) (30)
Composite 40/153 (26.1%)
Death 13/153 (8.5%)
MI 12/153 (7.8%)
Hospitalization 15/153 (9.8%)
SIRIUS (SES vs. BMS) (31)
Composite 46/533 (8.6%)
Death 5/533 (0.9%)
MI 15/533 (2.8%)
Target lesion revascularization 22/533 (4.1%)
ST 4/533 (0.8%)
TRITON–TIMI 38 (prasugrel vs. clopidogrel in ACS) (25)
Composite 644/6,813 (9.5%)
CV death 115/6,813 (1.7%)
Nonfatal MI 471/6,813 (6.9%)
Nonfatal stroke 58/6,813 (0.8%)
eterogeneity is derived from Cochran’s Q chi-square test and is implied at p 0.10; I2 quantifies t
ACS acute coronary syndromes; BMS bare-metal stent; CAD coronary artery disease; CV ca
hrombosis; STEMI  ST-segment elevation myocardial infarction.33)—an arguably implausible conjecture. rIt is apparent from these analyses that important
nformation regarding the individual component end
oints may be obscured by combining them into a
omposite, which often biases the analysis in favor of the
east important component. To avoid this, data on all
ndividual components must be provided, preferably both
ncluding and excluding double counting to permit
onhierarchical and hierarchical composite end point
nalysis, respectively. Individual component analysis
hould be done to ensure that any 1 or more components
eet statistical significance. Ideally, all components
hould demonstrate evidence of significant benefit (as in
he HOPE trial). At the very least, the composite end
oint should be impacted favorably (p  0.05), and
vidence of harm in the most important component such
s death or irreversible morbidity (nonfatal MI or stroke)
hould be excluded. One can put a limit of tolerable
nferiority, for example, upper 95% CI not to exceed a
Control OR 95% CI
Heterogeneity
p Value I2
215/1,106 (19.4%) 0.78 0.63–0.97 0.34 6%
39/1,106 (3.5%) 0.94 0.59–1.49
66/1,106 (5.9%) 0.65 0.44–0.96
110/1,106 (9.9%) 0.85 0.64–1.14
143/797 (17.9%) 0.68 0.52–0.90 0.29 17%
15/797 (1.9%) 1.03 0.50–2.13
51/797 (6.4%) 0.45 0.27–0.74
77/797 (9.7%) 0.82 0.57–1.16
588/4,588 (12.8%) 0.84 0.74–0.96 0.03 72%
234/4,588 (5.1%) 0.86 0.71–1.05
309/4,588 (6.7%) 0.73 0.62–0.88
188/4,588 (4.1%) 1.05 0.86–1.29
96/148 (64.9%) 0.19 0.12–0.31 0.001 93%
6/148 (4.1%) 2.20 0.81–5.94
17/148 (11.5%) 0.66 0.30–1.43
73/148 (49.3%) 0.11 0.06–0.21
110/525 (20.9%) 0.42 0.29–0.61 0.0001 90%
3/525 (0.6%) 1.65 0.39–6.93
17/525 (3.2%) 0.87 0.43–1.75
87/525 (16.6%) 0.22 0.13–0.35
2/533 (0.4%) 2.01 0.37–11.04
786/6,795 (11.6%) 0.80 0.71–0.89 0.05 67%
112/6,795 (1.7%) 1.02 0.79–1.33
618/6,795 (9.1%) 0.74 0.66–0.84
56/6,795 (0.8%) 1.03 0.71–1.49
act of heterogeneity. Data for the TRITON–TIMI 38 trial are first events (excludes double counting).
cular; MImyocardial infarction; RI refractory ischemia; SES sirolimus-eluting stent; ST stenthe impisk ratio of 1.2 to 1.3, as in noninferiority trials.
H
s
t
t
v
t
u
P
S
(
t
c
i
m
i
t
i
t
m
i
r
p
r
t
a
2
t
l
a
p
a
q
e
(
a
s
s
o
t
s
t
i
r
f
c
A
m
h
p
a
p
b
p
(
t
6
0
m
p
a
T
p
a
a
v
e
(
O
Sf
422 Kaul and Diamond JACC Vol. 55, No. 5, 2010
Limitations of Megatrials February 2, 2010:415–27owever, there are sample size implications, and the
trategy should be prospectively defined.
In summary, composite end points can be of value if both
heir requirements and their limitations are respected, and if
he results are reported in a straightforward manner, pro-
iding all information necessary for proper interpretation of
he trial. Suggested recommendations for their appropriate
se in clinical trials are summarized in Table 3.
erform Judicious Subgroup Analyses
ubgroup analysis means any evaluation of treatment effects
benefit or harm) for a specific end point in subdivisions of
he study population defined by various nonrandom baseline
haracteristics. As the number of RCTs has dramatically
ncreased over the last 3 decades, the exploration of treat-
ent effects in patient subgroups has also simultaneously
ncreased. While such analyses may provide useful informa-
ion for the care of patients and for future research, they also
ntroduce analytic and interpretive challenges that can lead
o overstated results, misleading conclusions, and subopti-
al care.
Several reviews have highlighted problems in the report-
ng of subgroup analyses (34–38). Assmann et al. (35)
eported shortcomings of subgroup analyses in 50 trials
ublished in 1997 in 4 leading medical journals. More
ecently, Parker et al. (36), who reviewed 67 cardiovascular
rials published between 1980 and 1997, and Herna´ndez et
l. (37), who reviewed 63 cardiovascular trials published in
002 and 2004, noted the same problems. Chief among
Figure 3 Weighted Primary Efficacy Composite
End Point Analysis for the TRITON–TIMI 38 Trial
Data used are first events (to exclude double counting) (see Table 2). The p values
are derived from a global z statistic under the assumption of no correlation among
the components of the composite end point (32,33). A sensitivity analysis across
myocardial infarction (MI) weighting is also shown (the weights of death and stroke
were fixed at 1.0 and 0.5, respectively). Only MI weights 0.4 achieve statistical
significance (p  0.05, values below the dotted line).hem include a lack of pre-specification, and testing of aarge number of subgroups without the use of statistically
ppropriate adjustment for interactions and multiple com-
arisons. Because a fairly large number of subgroup analyses
re often undertaken, the potential for false positive errors is
uite common. The collective probability of a false positive
rror (A) can be computed from the equation: A  1 
1  a)X, where X is the number of independent subgroup
nalyses and a is the false positive error for each individual
ubgroup analysis (usually 0.05) (39). For example, if 20
ubgroup analyses are conducted, the collective probability
f at least 1 false positive error is 0.64. Conversely, because
hese analyses are often underpowered because of small
ample size, false negative errors are also common. Finally,
hese analyses are usually nonrandomized, resulting in
mbalances in prognostic factors in subgroups. For these
easons, subgroup analyses should be considered exploratory
or informing future research and not conclusive to guide
linical practice.
The results of the CHARISMA (Clopidogrel for High
therothrombotic Risk and Ischemic Stabilization, Manage-
ent, and Avoidance) trial (40), summarized in Figure 4,
ighlight some of the major caveats that challenge the inter-
retation of subgroup analyses. In this trial, long-term dual
ntiplatelet therapy with clopidogrel was compared with
lacebo for patients without overt atherothrombotic disease
ut with multiple risk factors (asymptomatic) and for
atients with clinically evident atherothrombotic disease
symptomatic) on the background of aspirin treatment. In
he overall cohort, the rate of the primary end point was
.8% with clopidogrel and 7.3% with placebo (relative risk:
.93, 95% CI: 0.83 to 1.05, p  0.22), the rate of TIMI
ajor bleeding was higher with clopidogrel (2.1% vs. 1.3%,
 0.001), and the rate of death from cardiovascular causes
lso was higher with clopidogrel (3.9% vs. 2.2%, p  0.01).
he rate of the primary end point among asymptomatic
atients was 6.6% with clopidogrel and 5.5% with placebo,
nd it was 6.9% with clopidogrel and 7.9% with placebo
mong symptomatic patients. An interaction analysis re-
ealed a statistically significant heterogeneity of treatment
ffects in the symptomatic versus asymptomatic subgroup
interaction term 0.73, 95% CI: 0.54 to 1.00, p  0.045).
n the basis of these findings, the CHARISMA investi-
uggested Recommendationsor Use of Composit End PointsTable 3 Suggested Rec mmendationsfor Use of Composite End Points
Justify the validity of individual components.
Avoid clinically unimportant or uncertain outcomes.
Avoid components unlikely to be impacted by therapy.
Avoid combining efficacy outcomes with safety outcomes.
Report primary composite end point and individual components separately,
preferably both hierarchical and nonhierarchical counts.
Examine treatment-by-end-point interaction by a formal assessment of
heterogeneity.
Weigh components prospectively relative to their clinical importance.
Conduct and report sensitivity analyses relative to weight of the component
driving the composite end point.
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February 2, 2010:415–27 Limitations of Megatrialsators concluded that “a subgroup analysis suggested that
lopidogrel was beneficial with respect to the primary
fficacy end point in patients who were classified as symp-
omatic . . .” (40). Are these conclusions justified?
Although the subgroup analysis in the CHARISMA trial
as pre-specified, the subgroup classification was biologi-
ally plausible—high-risk symptomatic patients being more
ikely to benefit than low-risk symptomatic patients—and a
roper interaction test was conducted, 3 limitations still
erit consideration. First, the study failed to reach a
tatistical significance in the pre-specified overall analysis.
n such cases, it is generally not a good idea to perform
ubgroup analysis because the risk of false positive results
ncreases (you have, so to speak, already used up all of the
re-specified type I error to which you are entitled) (41).
he probability of a false positive error is directly related to
he number of subgroups tested (39). These caveats apply
qually to a post-hoc analysis of the CHARISMA trial that
oncluded that dual antiplatelet therapy provided significant
enefit in patients with documented prior MI, stroke, or
ymptomatic peripheral arterial disease (the so-called
APRIE-like cohort) (42). Positive subgroups within neg-
tive trials such as the CHARISMA study are virtually
lways the result of confounding or bias, especially post-hoc
efined subgroups (43).
Second, a key principle for interpretation of subgroup
esults is that quantitative interactions in which 1 treatment
s always better than the other, but by various degrees
differences in degree but not direction), are much more
redible than qualitative interactions (differences in direc-
ion) in which 1 treatment is better than the other for 1
ubgroup of patients and worse for the other subgroup of
atients (34)—the type of interaction observed in the
HARISMA study. Furthermore, quantitative interactions
re likely to be truly present whether or not they are
pparent, whereas apparent qualitative interactions should
enerally be disbelieved as they are seldom replicated con-
istently (34). Therefore, the overall trial result (a nonsig-
Figure 4 Subgroup Analysis for the CHARISMA Trial
The rate of the primary end point among asymptomatic patients (with multiple ath
brovascular, or peripheral arterial disease) is shown as hazard ratio (HR) and 95%
parisons is shown as an interaction term with 95% CI and p value.ificant treatment effect in the CHARISMA study) is ssually a better guide to the direction of effect in subgroups
han the apparent effect observed within a subgroup (sig-
ificant treatment benefit in symptomatic subgroup in the
HARISMA study).
Third, the subgroup analysis was not adjusted for multi-
le comparisons. Although a marginal treatment effect for
econdary prevention in symptomatic patients was sug-
ested by the subgroup analysis in the CHARISMA study
p  0.045), when adjusted for multiple subgroup analyses,
he corrected p value of 0.60 failed to reveal a differential
reatment effect in symptomatic versus asymptomatic pa-
ients (39). Had the interaction tests been assessed with a
riterion of 0.05 divided by 20 (0.0025) to account for the
act that 20 comparisons were conducted (the so-called
onferroni correction), none would have come close to
eaching statistical significance (39). The caveats enunciated
n an accompanying editorial (44) and a statistical perspec-
ive (39) highlight the problems with uncorrected multiple
ubgroup comparisons, leading the latter writer to conclude
hat “overstating the results of subgroup analyses can mis-
nform future research and lead to suboptimal clinical
ractice.”
Consider another example—the TACTICS–TIMI 18
rial, in which the overall results with regard to the primary
fficacy triple end point favored early invasive management
ver early conservative management in patients with non–
T-segment elevation ACS (7). A secondary objective of
his study was to test prospectively the validity of the
troponin hypothesis,” namely, to determine if benefits of
nvasive management were limited to troponin-positive
atients (7,45). As shown in Figure 5, the treatment by
roponin T subgroup interaction test was highly significant
p  0.003), indicating a hazard ratio of 1.13 in the
roponin-negative subgroup and 0.61 in the troponin-
ositive subgroup at 6-month follow-up. With such a highly
ignificant interaction test, the investigators judged the early
nvasive strategy to be beneficial in the troponin-positive
ubgroup. Encouraged by these results and in light of
mbotic risk factors) and symptomatic patients (with documented coronary, cere-
ence interval (CI). The result of subgroup analysis unadjusted for multiple com-erothro
confidimilar findings observed in a post-hoc analysis in the
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Limitations of Megatrials February 2, 2010:415–27RISC-II (Fast Revascularization During Instability in
oronary Artery Disease) trial, the investigators concluded
hat the “measurement of troponin at the time of presenta-
ion is useful in determining the optimal treatment strategy”
7,45). Accordingly, the treatment guidelines were upgraded
o reflect these findings, and an early invasive strategy was
ndorsed as a Class IA recommendation for patients with
uspected ACS and elevated troponin level with or without
T-segment depression or other high-risk features (11).
n independent confirmation of these findings was con-
ucted in the ICTUS (Invasive Versus Conservative Treat-
ent in Unstable Coronary Syndromes) trial. Although the
esign of the ICTUS trial (46) was similar to that of the
ACTICS–TIMI 18 study (except that enrollment was
imited to patients with elevated troponins), the results
roved to be different. The overall hazard ratio for the
CTUS trial was 1.07, showing no apparent treatment
enefit for troponin-positive patients, thereby calling the
trategy of early angiography for all patients with raised
roponin into question. No differences in patient baseline
haracteristics, end point criterion, or concomitant therapy
except for higher statin and clopidogrel use in the ICTUS
tudy) between the TACTICS–TIMI 18 study and the
CTUS trial could explain the discrepant results.
The results of these trials remind us of the need to
onfirm the findings from subgroup analyses, even if they
re pre-specified and the results are as expected. This is
articularly true for qualitative interactions—the type re-
orted to be statistically significant in the TACTICS–
IMI 18 study for both troponin T and I (45). These types
f interactions are seldom replicable and are likely to be
purious. It is important to note that none of the quantita-
Figure 5 Subgroup Analysis for the TACTICS–TIMI 18 Trial
Outcomes at 30 days and at 6 months are stratified by treatment group and cardi
or urgent revascularization. p  0.01 at 30 days and p  0.003 at 6 months for
end point. CI  confidence interval; RR  risk ratio.ive interactions reported for the death or nonfatal MI end eoint at both 30 days and 6 months in the TACTICS–
IMI 18 trial were statistically significant (7,45) (Fig. 5).
hese results are much more likely to be credible and
uggest no treatment by troponin subgroup interaction. The
esson to be learned here is that a trial is typically designed
o detect an effect in the whole population and that the most
eliable estimate of a subgroup’s results is still the overall
esults, not the estimate of a particular subgroup. The
rincipal value of subgroup analysis is to assess the robust-
ess of the primary conclusions by demonstrating consis-
ency within the subgroups, not to demonstrate inconsis-
encies in one or another arbitrary subgroup. Subgroup
ndings should be regarded with suspicion unless they are
ndependently confirmed. Failure to recognize the capri-
iousness of random variation often leads to premature
cceptance of the results, risking the adoption of inferior or
nnecessarily costly treatments (16).
The results of 2 recently published large RCTs (25,47)
ffer yet another example of how an improper interpretation
f the results of subgroup analyses can potentially lead to
isleading conclusions. The results from the TRITON–
IMI 38 study showed a treatment benefit with prasugrel
ver clopidogrel with regard to the efficacy end point.
owever, a bleeding hazard was also observed with prasu-
rel. A post-hoc exploratory subgroup analysis was con-
ucted to identify patients at higher risk of bleeding (history of
rior stroke/transient ischemic attack, body weight60 kg, or
ge75 years). Based on the results, the investigators stated
hat “with exclusion of patients with prior stroke/transient
schemic attack and dose reduction in the elderly (age 75
ears) and those with low body weight (60 kg), the
leeding risk with prasugrel will be minimized” (25). Nev-
onin T (TnT) level. The primary end point was death, myocardial infarction (MI),
ction between treatment group and cardiac TnT level with respect to the primaryac trop
interartheless, although the high-risk subgroup was numerically
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February 2, 2010:415–27 Limitations of Megatrialst a higher risk for bleeding with prasugrel (42% vs. 24%
elative increase in the non–high-risk subgroup), the
etween-group difference was not statistically significant
interaction p  0.64). In contrast, the between-group
ifference in ischemic events (26% decrease vs. 2% increase
n the high-risk subgroup, interaction p  0.008) and net
linical benefit (20% improvement vs. 7% worsening in the
igh-risk subgroup, interaction p  0.006) was significantly
n favor of prasugrel in the non–high-risk subgroup. Sim-
larly, the improvement in net clinical benefit in the sub-
roup without versus with a history of stroke or transient
schemic attack was driven by greater efficacy, not improved
afety.
In conclusion, in the TRITON–TIMI 38 trial, exclusion
f high-risk characteristics identified patients with im-
roved efficacy, not reduced bleeding risk, associated with
rasugrel, thereby questioning the claims of the trial inves-
igators. Combining the efficacy with the safety end point
nto a “net clinical benefit” end point serves to obscure this
ubtle, but important, distinction. This has important im-
lications for regulatory approval and clinical practice.
The results of the SYNTAX (Synergy Between Percuta-
eous Coronary Intervention With Taxus and Cardiac
urgery) trial showed that CABG, as compared with
ercutaneous coronary intervention (PCI) using the Taxus
rug-eluting stent (Boston Scientific, Natick, Massachu-
etts), is associated with a lower rate of MACE or cerebro-
ascular events at 1 year among patients with 3-vessel or left
ain coronary artery (LMCA) disease, or both (47). A
ost-hoc subgroup analysis showed a trend toward lower
vents with PCI in cases with anatomically simple LMCA
isease (LMCA only and LMCA plus single-vessel dis-
ase), compared with CABG-treated patients. These results
ave prompted many interventional cardiologists to choose
CI with stenting as a good treatment option for patients
ith LMCA disease (48,49). However, as shown in Figure
Figure 6 Subgroup Analysis for the SYNTAX Trial
The primary outcome (composite of death, nonfatal myocardial infarction [MI], non
cularization (percutaneous coronary intervention [PCI] vs. coronary artery bypass g
which includes left main (LM) plus 3-vessel disease (3VD), LM cohort subdivided i
unadjusted for multiple comparisons is shown; the dotted line represents the ove, there was overlap between the treatment effect in the
MCA only cohort (interaction p  0.51) or LMCA plus
ingle-vessel disease cohort (interaction p  0.10) and the
ffect in the overall cohort. Because the primary end point
ailed to reach a statistical verdict in favor of PCI, the
stimate of treatment effect in the overall cohort is the most
eliable estimate of treatment effect in the LMCA sub-
roup. On the basis of these results, it is generally not
dvisable to draw any inferences regarding PCI being the
referred treatment strategy for patients with LMCA dis-
ase (49).
Despite repeated discussion of the potential problems
ssociated with subgroup analysis and published guidelines
o improve the quality of subgroup analyses, a recent
nalysis of 97 trials published in the New England Journal of
edicine in 2005 and 2006 showed that problems and
mbiguities persist (50). In approximately two-thirds of the
ublished trials, it was unclear whether any of the reported
ubgroup analyses were pre-specified or post hoc. In more
han one-half of the trials, it was unclear whether interac-
ion tests were used, and in approximately one-third of the
rials, within-level results were not presented in a consistent
ay. Recommendations on when and how subgroup anal-
ses should be conducted and reported are shown in
able 4. The goal is to avoid unwarranted data dredging and
ncrease the clarity and completeness of the information
eported, thereby improving the interpretability of the
ndings.
onclusions
he randomized controlled clinical trial has become the
old standard scientific method for the evaluation of diag-
ostic and treatment interventions. However, there are a
umber of limitations that challenge the interpretation of
he results of these trials. Careful attention to these caveats
troke, and repeat revascularization) at 12 months is stratified by mode of revas-
rgery [CABG]) and the anatomic subset of coronary artery disease: overall cohort,
lated LM and LM plus 1-vessel disease (1VD), and 3VD (48). Interaction p value
treatment effect. CI  confidence interval.fatal s
raft su
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Limitations of Megatrials February 2, 2010:415–27s not only key for critical evaluation of the literature, but it
lso has implications for the care and treatment of patients,
nd for the development and implementation of practice
uidelines and reimbursement policy. Misinterpreting the
esults of trials can misinform future research and lead to
uboptimal clinical practice.
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